Clinical importance of patient-reported outcome measures in severe asthma: results from U-BIOPRED.
Options
BORIS DOI
Date of Publication
December 20, 2024
Publication Type
Article
Division/Institute
Contributor
Meys, Roy | |
Franssen, Frits M E | |
Van 't Hul, Alex J | |
Bakke, Per S | |
Caruso, Massimo | |
Dahlén, Barbro | |
Fowler, Stephen J | |
Howarth, Peter H | |
Horváth, Ildikó | |
Krug, Norbert | |
Behndig, Annelie F | |
Musial, Jacek | |
Shaw, Dominick E | |
Montuschi, Paolo | |
Zee, Anke H Maitland-van der | |
Sterk, Peter J | |
Roberts, Graham | |
Kermani, Nazanin Z | |
Incalzi, Raffaele A | |
Louis, Renaud | |
Andersson, Lars I | |
Wagers, Scott S | |
Dahlén, Sven-Erik | |
Chung, Kian Fan | |
Adcock, Ian M | |
Spruit, Martijn A |
Series
Health and Quality of Life Outcomes
ISSN or ISBN (if monograph)
1477-7525
Publisher
BioMed Central
Language
English
Publisher DOI
PubMed ID
39707320
Uncontrolled Keywords
Description
Rationale
Knowledge about the clinical importance of patient-reported outcome measures (PROMs) in severe asthma is limited.Objectives
To assess whether and to what extent asthma exacerbations affect changes in PROMS over time and asthma-specific PROMs can predict exacerbations in adult patients with severe asthma in usual care.Methods
Data of 421 patients with severe asthma (62% female; mean age 51.9 ± 13.4 years; mean FEV1 67.5 ± 21.3%pred) from the U-BIOPRED cohort were analyzed. The included PROMs were: Asthma Control Questionnaire (ACQ5); Asthma Quality of Life Questionnaire (AQLQ); Hospital Anxiety and Depression scale (HADS); Epworth Sleepiness Scale (ESS); Medication Adherence Report Scale (MARS); Sino-Nasal Outcomes Test (SNOT20). Participants were assessed at baseline and after 12-18 months of usual care.Results
PROMs showed very weak to weak correlations with clinical characteristics such as age, body mass index, FEV1, FeNO and eosinophilic cell count. Patients presenting no exacerbations during follow-up showed a statistically significant improvement in all PROMs (except for MARS), whereas individuals experiencing > 2 exacerbations showed a deterioration. Baseline ACQ5 was a predictor of exacerbations with an AUC of 0.590 (95%CI 0.514-0.666).Conclusions
The association of PROMs with clinical measures was poor in severe asthmatics. Moreover, PROMs were prone to changes in usual care, with exacerbations playing a key role. PROMs need to be systematically evaluated in severe asthma to improve clinical care based on specific patient's needs.
Knowledge about the clinical importance of patient-reported outcome measures (PROMs) in severe asthma is limited.Objectives
To assess whether and to what extent asthma exacerbations affect changes in PROMS over time and asthma-specific PROMs can predict exacerbations in adult patients with severe asthma in usual care.Methods
Data of 421 patients with severe asthma (62% female; mean age 51.9 ± 13.4 years; mean FEV1 67.5 ± 21.3%pred) from the U-BIOPRED cohort were analyzed. The included PROMs were: Asthma Control Questionnaire (ACQ5); Asthma Quality of Life Questionnaire (AQLQ); Hospital Anxiety and Depression scale (HADS); Epworth Sleepiness Scale (ESS); Medication Adherence Report Scale (MARS); Sino-Nasal Outcomes Test (SNOT20). Participants were assessed at baseline and after 12-18 months of usual care.Results
PROMs showed very weak to weak correlations with clinical characteristics such as age, body mass index, FEV1, FeNO and eosinophilic cell count. Patients presenting no exacerbations during follow-up showed a statistically significant improvement in all PROMs (except for MARS), whereas individuals experiencing > 2 exacerbations showed a deterioration. Baseline ACQ5 was a predictor of exacerbations with an AUC of 0.590 (95%CI 0.514-0.666).Conclusions
The association of PROMs with clinical measures was poor in severe asthmatics. Moreover, PROMs were prone to changes in usual care, with exacerbations playing a key role. PROMs need to be systematically evaluated in severe asthma to improve clinical care based on specific patient's needs.
File(s)
| File | File Type | Format | Size | License | Publisher/Copright statement | Content | |
|---|---|---|---|---|---|---|---|
| s12955-024-02321-3.pdf | text | Adobe PDF | 2.29 MB | published |